Thrombotic diseases, in particular cardiovascular and cerebrovascular thrombotic diseases, have become the top cause of death in the population of China, and their incidence has increased, seriously endangering human health.

China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Italian diagnostic firm DiaSorin on Wednesday reported a 32 percent year-over-year jump in revenues for the second quarter of 2022.

Following extraordinary demand for rapid COVID-19 antigen testing in 2021, Siemens Healthineers reported on Wednesday that the company's fiscal third quarter COVID-19 testing revenue declined sharply

Based on the close and good cooperative relationship between Shanghai Runda Medical Technology Co., Ltd. and Ortho-Clinical Diagnostics for many years, in order to speed up the launch of Ortho related IVD equipment and reagents in Chinese market

Genomenon said Tuesday that it has been named the exclusive gene curation partner for Rady Children's Institute for Genomic Medicine's (RCIGM) recently launched BeginNGS newborn screening panel.

MDxHealth said on Tuesday that it has acquired the Oncotype DX GPS prostate cancer testing business from Exact Sciences subsidiary Genomic Health in a deal worth up to $100 million.

Daan Gene disclosed its semi-annual performance report on 28 July. In the first half of the year, the company achieved a total operating income of 6.676 billion CNY, a year-on-year increase of 91.68%

The prefrontal cortex region of the human brain is responsible for a range of complex functions from decision-making to certain types of memory. When something goes wrong in this part of the brain, it can be very detrimental for cognition and behavior.

PerkinElmer Inc (PKI.N) on Monday agreed to sell three of its businesses to private equity firm New Mountain Capital for up to $2.45 billion in cash, as it looks to focus on its life sciences and diagnostics businesses under a new name.

Rising demand for core diagnostics offset better-than-feared declines in COVID-19 test sales, shedding light on the companies’ post-pandemic futures.

Meridian Bioscience said on Friday that the Emergency Use Authorization for its Revogene SARS-CoV-2 molecular test has been reissued by the US Food and Drug Administration.